• 6 min read
• Published on 25 July 2025
Listen to article
6:52Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
I often look at the world of business and see a great deal of fuss. Factories churning out widgets, lorries stuck on motorways, warehouses full of stock that might never sell. It all seems so terribly complicated, so messy. It makes you wonder if there isn't a cleaner, more elegant way to make a pound. And it turns out, for a clever few, there is. They’ve decided to skip the physical clutter and instead own the one thing that truly matters, the idea itself.
Think about it. What if your entire business asset was an idea, protected by a cast-iron legal document? You wouldn't need a single factory floor or a fleet of delivery vans. This is the rather beautiful world of intellectual property royalties. Take a company like Royalty Pharma. They don't spend a decade and a king's ransom trying to invent a new drug. That’s a mug’s game. Instead, they wait for someone else to do the hard work, then they swoop in and buy a slice of the future revenue. Every time a pharmacy dispenses that drug, a little bit of cash flows their way. It’s like being a landlord for a blockbuster medicine.
The same principle applies in less clinical fields. Warner Music Group doesn’t press vinyl records anymore, not really. They own the rights to the songs. Every time you stream a classic on your phone, they get paid. The song is the asset, and it costs nothing to store. This asset-light model is the envy of any business stuck dealing with rising material costs and supply chain nightmares. Their profit margins aren't eroded by physical world problems, because their business barely exists in the physical world.
Now, you might think an idea is a flimsy thing to build a business on. But this is where the magic happens. These revenue streams are not based on goodwill, they are enforced by patents and copyrights. This isn't just a business model, it's a legally protected monopoly, at least for a while. A company like Innoviva, which holds patents for respiratory therapies, has its income written into contracts. When a partner company uses its patented technology, they are legally obligated to pay. It’s not a discretionary purchase that a consumer might skip in a downturn. It’s a contractual obligation.
This provides a level of income predictability that most chief executives can only dream of. While other companies are tossed about by the storms of economic cycles and fickle consumer trends, these royalty collectors often enjoy a much smoother ride. Their income is baked in, protected by the full force of the law.
Of course, it’s not a risk-free paradise. Nothing in investing ever is. The very legal protections that make these companies strong also have a built-in expiry date. A patent typically lasts for 20 years, and when it expires, that gusher of cash can slow to a trickle overnight as generic competition floods in. This is the infamous ‘patent cliff’ that keeps pharmaceutical investors awake at night. In the world of entertainment, the risk is different but no less real. A song that’s a hit today could be forgotten tomorrow. Tastes change, and a catalogue of copyrights is only valuable as long as people want to listen to it. You’re betting on cultural relevance, which can be a notoriously fickle beast.
To me, the appeal is clear, provided you go in with your eyes open. You’re looking at businesses with potentially high margins and recurring revenues, insulated from a lot of the grubby realities of manufacturing and logistics. The key, I think, is not to bet the farm on a single patent or one-hit-wonder. Diversification is paramount. You might find that a collection of companies, spanning biotech, media, and technology, could offer a more balanced approach to this theme. A portfolio of Intellectual Property Titans, for instance, might spread the risk across different types of ideas and industries.
Ultimately, investing here requires a different mindset. You aren't analysing factory output or inventory levels. You are judging the quality and longevity of an idea. It’s a fascinating challenge, and for those who get it right, the potential rewards could be substantial. Just remember, you’re investing in something you can’t see or touch, which requires a little more faith than buying a piece of a company that makes bricks.
View the full Basket:Intellectual Property
View the full Basket:Intellectual Property
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article